Arcutis Biotherapeutics receives FDA approval for ZORYVE
Arcutis Biotherapeutics has received US FDA approval for NDA for ZORYVE topical foam, 0.3%, to treat seborrheic dermatitis
Stay updated with breaking news from Patrick Burnett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arcutis Biotherapeutics has received US FDA approval for NDA for ZORYVE topical foam, 0.3%, to treat seborrheic dermatitis
The approval of the once-daily, steroid free foam marks the first approval of a drug by the FDA for the skin condition.
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval for a drug.
Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval for a drug.